Skip to main content

Advertisement

Log in

Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials

  • Review – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Significant improvement in survival outcome with the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has been shown in advanced non-small cell lung cancer (NSCLC) patients compared with chemotherapy. However, the full spectrum of toxic events of PD-1/PD-L1 inhibitors was not well characterized. We conducted a comprehensive meta-analysis to state the safety profile of PD-1/PD-L1 inhibitors in NSCLC, and identify the exact incidence and relative risk (RR) of both summary and detailed AEs.

Materials and methods

Electronic databases (PubMed, EMBASE and the Cochrane library databases) and major conference proceedings were systematically searched for all clinical trials in lung cancer using PD-1/PD-L1 inhibitors. Eligible studies included randomized controlled trials (RCTs) comparing PD-1/PD-L1 inhibitors with chemotherapy in NSCLC patients reporting all-grade (1–4) or high-grade (3–4) AEs [toxic symptoms, hematologic toxicities, and immune-related AEs (irAEs)], treatment discontinuation due to toxicities, or toxic deaths. The pooled incidence, RR, and corresponding 95% confidence interval (CI) of toxicity outcomes were calculated.

Results

A total of 4413 patients from 8 RCTs (3 with nivolumab; 2 with atezolizumab, and 3 with pembrolizuma) were included. In terms of summary toxic events, PD-1/PD-L1 inhibitors had a significantly lower risk of any all-grade AEs (66.20 vs. 86.08%; RR 0.77) and high-grade AEs (14.26 vs. 43.53%; RR 0.32), treatment discontinuation (5.94 vs. 13.92%; RR 0.44), and toxic deaths (0.48 vs. 1.12%; RR 0.45) than chemotherapy. With regard to detailed toxic events, the risk of toxic symptoms (including all-grade fatigue, nausea, constipation, diarrhea and peripheral sensory neuropathy; high-grade fatigue, anorexia, diarrhea and peripheral sensory neuropathy) and hematologic toxicities (including all-grade and high-grade neutropenia, thrombocytopenia, and anemia) from PD-1/PD-L1 inhibitors was significantly lower than from chemotherapy. However, there was a small but significantly increased risk of irAEs, including all-grade rash, pruritus, colitis, hypothyroidism, hyperthyroidism, ALT/AST elevations and pneumonitis, as well as high-grade pneumonitis.

Conclusion

PD-1/PD-L1 inhibitors are generally safer and better tolerated than chemotherapy for patients with NSCLC with regard to summary toxic events, detailed toxic symptoms and hematologic toxicities. However, PD-1/PD-L1 inhibitors can generate a unique spectrum of irAEs, and several of them can be severe and even life-threatening. Clinicians should be aware of the risk of these AEs, as they may have a potentially negative impact on the patients’ quality of life and survival outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

AEs:

Adverse events

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

ASCO:

American Society of Clinical Oncology

CTCAE:

The Common Terminology Criteria for Adverse Events version

CI:

Confidence interval

FDA:

Food and Drug Administration

irAEs:

Immune-related AEs

PD-1:

Programmed death 1

PD-L1:

Programmed death ligand 1

RR:

Relative risk

RCTs:

Randomized controlled trials

References

  • Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  CAS  Google Scholar 

  • Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106

    Article  CAS  Google Scholar 

  • Chae YK, Arya A, Iams W et al (2018) Immune checkpoint pathways in non-small cell lung cancer. Ann Transl Med 6(5):88

    Article  Google Scholar 

  • Cousin S, Italiano A (2016) Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res 22(18):4550–4555

    Article  CAS  Google Scholar 

  • De Velasco G, Je Y, Bosse D et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312–318

    Article  Google Scholar 

  • DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  CAS  Google Scholar 

  • Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  Google Scholar 

  • Fay AP, Moreira RB, Nunes Filho PRS et al (2016) The management of immune-related adverse events associated with immune checkpoint blockade. Expert Rev Qual Life Cancer Care 1(1):89–97

    Article  Google Scholar 

  • Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–1846

    Article  CAS  Google Scholar 

  • Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550

    Article  CAS  Google Scholar 

  • Higgins JP (2011) The Cochrane Collaboration. 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://www.cochrane-handbook.org. Accessed 21 Jun 2018

  • Iwai Y, Hamanishi J, Chamoto K et al (2017) Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24(1):26

    Article  Google Scholar 

  • Li A, Wei ZJ, Ding H et al (2017) Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials. Oncotarget 8(34):57365–57378

    PubMed  PubMed Central  Google Scholar 

  • Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148

    Article  CAS  Google Scholar 

  • Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391

    CAS  PubMed  Google Scholar 

  • National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) 4.0 Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accessed 21 Jun 2018

  • O’Kane GM, Labbe C, Doherty MK et al (2017) Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist 22(1):70–80

    Article  Google Scholar 

  • Pai-Scherf L, Blumenthal GM, Li H et al (2017) FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 22(11):1392–1399

    Article  CAS  Google Scholar 

  • Panic N, Leoncini E, de Belvis G et al (2013) Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PloS One 8(12):e83138

    Article  Google Scholar 

  • Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

    Article  CAS  Google Scholar 

  • Reeve BB, Mitchell SA, Dueck AC et al (2014) Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 106(7)

    Article  Google Scholar 

  • Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265

    Article  Google Scholar 

  • Thompson JA (2018) New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Cancer Netw: JNCCN 16(5 s):594–596

    Article  Google Scholar 

Download references

Funding

This study was supported by the Science and Technology Support Program of Sichuan Province (No.2016CZYD0001 to Wemin Li and No.2016SZ0073 to PanwenTian).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Weimin Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest regarding the present study.

Ethical approval

The article does not contain any studies with human participants performed by any of the authors.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, W., Wang, Z., Tian, P. et al. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 144, 1851–1859 (2018). https://doi.org/10.1007/s00432-018-2707-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-018-2707-4

Keywords

Navigation